chf6333
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03056326)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte elastaseINHIBITOR
ELANE inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)C1=C(C)N(C2=NNC(=O)N2[C@@H]1C3=CC=C(C=C3CC[N+](C)(C)C)C#N)C4=CC=CC(=C4)C(F)(F)F- Mol. weight
- 541.5448 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS00174624E2 ↗
Also known as
- chf6333
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06166056 | Phase 1/Phase 2 (Phase 2) | Nov 29, 2023 | Chiesi, University of Dundee |
| NCT04010799 | Phase 1 | May 27, 2019 | Chiesi |
| NCT03056326 | Phase 1 | Nov 1, 2016 | Chiesi, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiesi | For profit | 3 | 3 | 2 | 2016 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2016 |
| University of Dundee | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1